Publication: Tratamiento con rituximab en pacientes con artritis reumatoide en la práctica clínica. Estudio RITAR
Loading...
Official URL
Full text at PDC
Publication Date
2019-11-21
Authors
Advisors (or tutors)
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
Universidad Complutense de Madrid
Citations
Exportar
Abstract
La artritis reumatoide (AR) es una enfermedad sistémica autoinmune que produce inflamación crónica articular. La prevalencia global es 0,50-1,00% en adultos. La AR es una enfermedad compleja e implica factores ambientales que desencadenan la enfermedad en individuos genéticamente susceptibles, destacando el tabaquismo, la periodontitis por Phorphyromonas gingivalis y otros microorganismos.
La AR es una enfermedad simétrica poliarticular bilateral que cursa con dolor, inflamación y rigidez matutina. El diagnóstico es principalmente clínico, se debe realizar una exploración clínica completa y pruebas de laboratorio (VSG, PCR, FR, ACPA). El tratamiento contempla uso de fármacos antirreumáticos modificadores de la enfermedad (FAME) sintéticos convencionales, biológicos o dirigidos. Rituximab (RTX) es un anticuerpo monoclonal quimérico que se une específicamente al CD20 de células B y produce lisis celular. El tratamiento no es curativo, precisa la administración de ciclos sucesivos aunque el esquema no está claramente establecido...
Rheumatoid arthritis (RA) is an autoimmune systemic disease that causes chronic joint swelling. The overall prevalence is 0.50-1.00% in adults. RA is a complex disease and involves environmental factors that trigger this disease in genetically susceptible individuals. These factors are tobacco, periodontitis by Phorphyromonas gingivalis and probably other microorganisms. RA is a bilateral polyarticular symmetrical disease which main clinical manifestations are pain, inflammation and morning stiffness. Diagnosis is mainly clinical, a complete clinical exploration and laboratory tests (ESR, CRP, RF, ACPA) should be performed. The treatment includes the use of conventional synthetic, biological or targeted disease-modifying antirheumatic drugs (DMARDs). Rituximab (RTX) is a chimeric monoclonal antibody that binds specifically to CD20 molecule in B cells surface and deplete them. RTX treatment is not curative and need the administration of successive cycles, although the optimal therapeutic scheme is lacking...
Rheumatoid arthritis (RA) is an autoimmune systemic disease that causes chronic joint swelling. The overall prevalence is 0.50-1.00% in adults. RA is a complex disease and involves environmental factors that trigger this disease in genetically susceptible individuals. These factors are tobacco, periodontitis by Phorphyromonas gingivalis and probably other microorganisms. RA is a bilateral polyarticular symmetrical disease which main clinical manifestations are pain, inflammation and morning stiffness. Diagnosis is mainly clinical, a complete clinical exploration and laboratory tests (ESR, CRP, RF, ACPA) should be performed. The treatment includes the use of conventional synthetic, biological or targeted disease-modifying antirheumatic drugs (DMARDs). Rituximab (RTX) is a chimeric monoclonal antibody that binds specifically to CD20 molecule in B cells surface and deplete them. RTX treatment is not curative and need the administration of successive cycles, although the optimal therapeutic scheme is lacking...
Description
Tesis doctoral de la Universidad Complutense de Madrid, Facultad de Farmacia, Departamento de Farmacología, Farmacognosia y Botánica, leída el 20-09-2019